A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Whole Brain Radiation Therapy (WBRT) in treating patients with brain metastases.
Brain Diseases|Brain Neoplasms|Central Nervous System Diseases|Neoplasm Metastasis|Nervous System Neoplasms
DRUG: ABT-888|RADIATION: Whole Brain Radiation Therapy
Determine the maximum tolerated dose of ABT-888 in combination with whole brain radiation therapy, ABT-888 will be dose escalated until the largest dose is reached that is felt to be safe based on safety information from all subjects.
Safety Assessment Physical and Neurological Exam, be performed at all study visits, final and follow-up visit|Safety Assessment Mini-Mental State Examination, be performed at all study visits, final and follow-up visit|Safety Assessment Laboratory testing, Chemistry and Hematology labs will be collected, be performed at all study visits, final and follow-up visit
This is a Phase 1, multicenter, dose-escalation study evaluating the safety, tolerability and pharmacokinetics of the PARP inhibitor ABT-888 in combination with conventional whole brain radiation therapy (WBRT) in the treatment of subjects with solid tumors metastatic to the brain.